General Information of Drug (ID: DMZR3OJ)

Drug Name
FBX-101 Drug Info
Indication
Disease Entry ICD 11 Status REF
Krabbe disease 8A44.4 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMZR3OJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Galactocerebrosidase (GALC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PBKR03 DM57HM7 Globoid cell leukodystrophy 8A44.4 Phase 1/2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Galactocerebrosidase (GALC) TT5IZRB GALC_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05739643) A Phase 1b Clinical Study of Intravenous AAVrh10 Vector Expressing GALC in Krabbe Subjects Who Previously Received Hematopoietic Stem Cell Transplantation (REKLAIM). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04693598) A Phase 1/2 Clinical Study of Intravenous Gene Transfer With an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic Stem Cell Transplantation (RESKUE). U.S.National Institutes of Health.
3 Clinical pipeline report, company report or official report of Passage Bio